Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

NCT02605915 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

98

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-Positive Metastatic Breast Cancer
HER2-Negative Metastatic Breast Cancer
Locally Advanced or Early Breast Cancer

Interventions

DRUG: Atezolizumab
DRUG: Carboplatin
DRUG: Docetaxel
DRUG: Pertuzumab
DRUG: Trastuzumab
DRUG: Trastuzumab emtansine
DRUG: Doxorubicin
DRUG: Cyclophosphamide

Sponsor

Hoffmann-La Roche